Takeda is dedicated to pharmaceutical innovation and tackling diseases for which there is currently no cure. We are expanding continuously into new fields of treatment and therapy, worldwide and in our region, where we focus on oncology, inflammatory bowel diseases and immunology.
Despite the progress made in the fight against cancer, serious unmet needs persist across many forms of the disease. Our deep understanding of patient needs, our scientific rigor, our resources and our agile business model optimally allow us to work quickly to meet the diverse needs of cancer patients, healthcare providers and systems, and to bring the next generation of cancer treatments to patients.
We know that our mission is not a quick or simple one, but we are up to the task: we aspire to cure cancer.
We have built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Takeda Belgium offers solutions for the treatment of patients suffering from multiple myeloma, Hodgkin’s disease and sALCL or systemic anaplastic large cell lymphoma.